Facebook Linkedin RSS Twitter Youtube
Home 2024

Biogen

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial
Drug Discovery

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data
Drug Discovery

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data

Lecanemab Approval for Early Alzheimer’s Disease Hits Roadblock in Europe
Drug Discovery

Lecanemab Approval for Early Alzheimer’s Disease Hits Roadblock in Europe

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
Drug Discovery

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing
Drug Discovery

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

StockWatch: Biogen Q1 Results Beat Expectations, for a Change
Drug Discovery

StockWatch: Biogen Q1 Results Beat Expectations, for a Change

Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe
Bioprocessing

Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe

StockWatch: Biogen’s Q4 Results Disappoint Analysts
Drug Discovery

StockWatch: Biogen’s Q4 Results Disappoint Analysts

Antibodies Take Center Stage in Alzheimer’s
Drug Discovery

Antibodies Take Center Stage in Alzheimer’s

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug
Drug Discovery

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug

123...21Page 1 of 21
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.